CONSOLIDATED STATEMENTS OF SHAREHOLDERS’/MEMBERS’ EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common stock	Common stock Cumulative Effect, Period of Adoption, Adjusted Balance	Additional paid-in capital	Additional paid-in capital Cumulative Effect, Period of Adoption, Adjusted Balance	Retained earnings	Retained earnings Cumulative Effect, Period of Adoption, Adjustment	Retained earnings Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss) Cumulative Effect, Period of Adoption, Adjusted Balance	Non-controlling interests	Non-controlling interests Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance at Dec. 28, 2019	$ 289,878		$ 284,069	$ 565	$ 565	$ 242,240	$ 242,240	$ 41,983		$ 36,174	$ 3,626	$ 3,626	$ 1,464	$ 1,464
Beginning balance (Accounting Standards Update 2016-02) at Dec. 28, 2019		$ (4,012)							$ (4,012)
Beginning balance (Accounting Standards Update 2016-13) at Dec. 28, 2019		$ (1,797)							$ (1,797)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,255							3,289					(34)
Other comprehensive (loss)	(13,544)										(13,544)		0
Equity-based compensation expense	508					508
Common stock issued in a business combination	809,000					809,000
Acquisition of subsidiary with noncontrolling interest	400												400
Ending balance at Sep. 26, 2020	1,083,688			565		1,051,748		39,463			(9,918)		1,830
Beginning balance at Jun. 27, 2020											(7,489)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,111
Other comprehensive (loss)	(2,298)
Ending balance at Sep. 26, 2020	1,083,688			565		1,051,748		39,463			(9,918)		1,830
Beginning balance at Dec. 26, 2020	1,106,360			565		1,055,172		31,975			16,528		2,120
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(19,932)							(19,939)					7
Other comprehensive (loss)	(9,085)										(9,085)
Equity-based compensation expense	983					983
Issuance of common stock upon initial public offering, net of underwriting discounts and commissions	661,500			1,082		660,418
Common stock issued upon underwriter's exercise of over-allotment	99,225			48		99,177
Repurchase of common stock	(42,977)			(21)		(42,956)
Exercise of stock options	25					25
Establishment of income tax receivable liability	(155,970)					(155,970)
IPO fees	(14,757)					(14,757)
Other	(63)					0							(63)
Ending balance at Mar. 27, 2021	1,625,309			1,674		1,602,092		12,036			7,443		2,064
Beginning balance at Dec. 26, 2020	1,106,360			565		1,055,172		31,975			16,528		2,120
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	48,321
Other comprehensive (loss)	(28,515)
Ending balance at Sep. 25, 2021	1,675,497			1,674		1,604,342		80,364			(12,047)		1,164
Beginning balance at Mar. 27, 2021	1,625,309			1,674		1,602,092		12,036			7,443		2,064
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	35,167							35,204					(37)
Other comprehensive (loss)	11,412										11,412		0
Equity-based compensation expense	1,028					1,028
At-Pac divestiture	(948)												(948)
Other	(26)					(25)					(1)
Ending balance at Jun. 26, 2021	1,671,942			1,674		1,603,095		47,240			18,854		1,079
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	33,086							33,124					(38)
Other comprehensive (loss)	(30,842)										(30,902)		60
Equity-based compensation expense	933					933
Exercise of stock options	314					314
Other	64										1		63
Ending balance at Sep. 25, 2021	$ 1,675,497			$ 1,674		$ 1,604,342		$ 80,364			$ (12,047)		$ 1,164